Lavrov says Russia is waiting for US to specify safe zones in SyriaRussian Politics & Diplomacy February 22, 14:59
Three S-400 batteries from Moscow region conduct firing practice at Ashuluk test siteMilitary & Defense February 22, 14:50
UN commissioner praises Russia for initiating Astana processWorld February 22, 14:28
Kremlin says Russia's constitution ensures women’s rights to run for presidentRussian Politics & Diplomacy February 22, 14:16
Russian army to fully switch over to Iskander tactical missile systems in 2017Military & Defense February 22, 14:13
Defense Ministry to form four divisions in 2017, including one to protect KurilsMilitary & Defense February 22, 13:42
SpaceX waves off space station cargo deliveryScience & Space February 22, 13:37
Over 80% of Russia’s missile units rearmed with Iskander tactical systemsMilitary & Defense February 22, 13:35
Kremlin disagrees with latest Amnesty International reportRussian Politics & Diplomacy February 22, 13:21
MOSCOW, August 19. /TASS/. Russia’s N.F. Gamalei Epidemiology and Microbiology Research Institute has launched clinical trials of anti-Ebola vaccines that will necessitate 4.8 million rubles (about $75,000), the official portal for government procurement said on Friday.
Pre-emptive vaccines against Ebola - Gum Evak and Gum Evak Combi are ready for human trials, the portal said. The main aim of the research is to assess post-vaccination immunity in patients at different points of time after inoculation. Under the forecasts, the research is to end by December 2017.
It was also said that the Gamalei institute had insured volunteers in clinical trials of the registered vaccines. Two million rubles ($31,282) would be paid if a volunteer died. Should a volunteer’s health be damaged leading to a first degree disability, the patient would receive 1.5 million rubles ($26,461), while a second-degree disability would enable him to be awarded one million rubles. However, in cases of third degree disability, the patient would receive 500,000 rubles.
The World Health Organization presented Russia’s pre-emptive vaccines against Ebola - Gum Evak and Gum Avak Combi - in Geneva on February 15. Russia launched work on vaccines in October 2014, and within 15 months, two vaccines were introduced showing maximum efficiency, full safety and high tolerability.
At the moment, the Russian vaccine is the only one that has been registered.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected.